STLN: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-election to the Board of the Directors of the Company (the “Board”) at its 2027 annual meeting of stockholders (the “Annual Meeting”). Mr. Hively is expected to continue to serve as a director of the Company until the Annual Meeting, but effective immediately, will no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee or any other committees of the Board. Mr. Hively’s decision not to stand for re-election is not the result of any disagreement between the Company and him on any matter relating to Company’s operations, policies or practices. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 1, 2026 STARLING ONCOLOGY, INC. By: /s/ Minh Merchant Name: Minh Merchant Title: Chief Legal Officer